Alligator Bioscience AB
The answer first
Does Alligator Bioscience beat the market?
No, Alligator Bioscience has not beaten the market over the last year.
The ranking · Quality, value and trend combined
Better than 6% of Nordic stocks
- Quality11
- Value59
- Trend1
No. 173 of 195 in healthcare
Max for seven days
Follow Alligator Bioscience with AuroraAurora lets you know at the next report. No card.
Both with dividends. Figures as of 18 November 2026. General analysis, not personal advice.
Follow your thesis
Ask Aurora about Alligator Bioscience
Your first answer is free, no account needed.
Do you own Alligator Bioscience, or are you thinking about it?
See it next to the rest of your portfolio, or build your first one with Alligator Bioscience and a few more. Free, no card.
Super Stock+44.6%In short
- Alligator Bioscience has fallen 95.6% over the past year, including dividends.
- Overall, Alligator Bioscience ranks better than 6% of Nordic stocks on quality, value and trend.
- The largest fall over the past three years was 100.0%. The price is 100.0% below its peak now.
What do analysts think of Alligator Bioscience?
Quality, value and trend
Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.
Quality, value and trend together. Better than 6% of Nordic stocks.
No. 173 of 195 in healthcare
Low Weaker accounts than most: low profitability, high debt or uneven results.
No. 184 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50
- Debt to equityBorrowings divided by equity2.69
- Asset turnoverSales divided by everything the company owns0.00
- Return on equityProfit divided by equity−354.3%
- Cash conversionOperating cash flow divided by profit–
The ranking is built on equity ratio, ROA and how steadily profit grows.
Medium Fair price: about the same as a typical Nordic stock.
No. 31 of 197 in healthcareTypical in healthcare: 20Typical in the Nordics: 50
- P/BPrice divided by equity0.2
- P/SPrice divided by sales19.0
- P/EPrice divided by earningsnegative earnings
- P/CFPrice divided by operating cash flownegative earnings
The ranking is built on P/E, P/B and P/S.
Low Headwind in the share price: it has done worse than most over the last year.
No. 196 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50
- 3 months−58.8%
- 6 months−93.9%
- 9 months−93.1%
- 12 months−95.6%
The ranking is built on 3, 6 and 12–1 months.
Return and risk
Return with dividends reinvested.
The funds that own Alligator Bioscience
2 funds we follow own Alligator Bioscience. The share is how much of the fund the stock makes up.
- Sweden2
From the funds' latest known holdings.
About Alligator Bioscience
Alligator Bioscience AB is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 11 employees.
Alligator Bioscience AB (publ), a research-based biotechnology company, develops antibody-based pharmaceuticals for cancer treatment in Belgium. The company develops Mitazalimab, a stimulatory antibody that targets CD40, which is in phase 3 clinical trial for the treatment of solid metastatic tumors, including pancreatic cancer; and ATOR-4066, tumor-directed bispecific antibody, developed using Neo-X-Prime technology platform for immunotherapy, which is in preclinical stage for the treatment of solid metastatic tumors.


See the full analysis of Alligator Bioscience.
The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.
Free forever · No card